9/12/2013 6:35:31 AM
Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB:SNTI) today announced financial results for the 12 months ended June 30, 2013 (“Fiscal 2013”).
Fiscal Fourth Quarter and Recent Highlights
•The Company completed the second cohort of patients in its Phase 1b/2a clinical trial for the treatment of multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma with SNS01-T, the Company’s lead drug candidate. In cohort 2, two multiple myeloma patients and one diffuse large B-cell lymphoma patient completed the required number of doses to be evaluable from the total of 4 patients enrolled.
Help employers find you! Check out all the jobs and post your resume.
comments powered by